Chiesi wins Italian approval for Cambridge's Xenazina

UK-based Cambridge Laboratories says that its distribution partner in Italy, Chiesi Farmaceutici SpA, has gained approval for Xenzina (tetrabenazine) from the Agenzia Italiana del Farmaco. The agent, which is also known as Nitoman in Germany and other key European territories and Xenazine in the UK and elsewhere, has been approved for the treatment of movement disorders associated with Huntington's disease and for moderate-to-severe tardive dyskinesia, both conditions for which there is a major unmet medical need. Cambridge licensed the dopamine depleting agent to Chiesi in 2003 for local commercialization. This approval follows on from the recent launches of the product in Germany and France and continues Cambridge's focus in specialist secondary care.